Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination chemotherapy regimen consisting of four components: - **Calcium folinate** (also known as leucovorin or folinic acid): a vitamin derivative that enhances the effectiveness of fluorouracil by stabilizing its binding to the target enzyme. - **Recombinant human endostatin**: an anti-angiogenic agent that inhibits tumor blood vessel formation, thereby restricting tumor growth. - **Fluorouracil (5-FU)**: a pyrimidine analog chemotherapy drug that interferes with DNA synthesis in rapidly dividing cancer cells. - **Irinotecan**: a topoisomerase I inhibitor chemotherapy drug that prevents DNA replication and transcription in cancer cells. The combination is used primarily for treatment of advanced or metastatic cancers such as colorectal cancer and gastric cancer. Calcium folinate improves the efficacy of fluorouracil. Recombinant human endostatin adds an anti-angiogenic mechanism to inhibit tumor vascularization, complementing the cytotoxic effects of fluorouracil and irinotecan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium folinate + recombinant human endostatin + fluorouracil + irinotecan.